Literature DB >> 11807820

Regulation of RNA polymerase II activity by CTD phosphorylation and cell cycle control.

Thomas Oelgeschläger1.   

Abstract

The carboxyl-terminal domain (CTD) of the largest subunit of mammalian RNA polymerase II (RNAP II) consists of 52 repeats of a consensus heptapeptide and is subject to phosphorylation and dephosphorylation events during each round of transcription. RNAP II activity is regulated during the cell cycle and cell cycle-dependend changes in RNAP II activity correlate well with CTD phosphorylation. In addition, global changes in the CTD phosphorylation status are observed in response to mitogenic or cytostatic signals such as growth factors, mitogens and DNA-damaging agents. Several CTD kinases are members of the cyclin-dependent kinase (CDK) superfamily and associate with transcription initiation complexes. Other CTD kinases implicated in cell cycle regulation include the mitogen-activated protein kinases ERK-1/2 and the c-Abl tyrosine kinase. These observations suggest that reversible RNAP II CTD phosphorylation may play a key role in linking cell cycle regulatory events to coordinated changes in transcription. Copyright 2002 Wiley-Liss, Inc.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 11807820     DOI: 10.1002/jcp.10058

Source DB:  PubMed          Journal:  J Cell Physiol        ISSN: 0021-9541            Impact factor:   6.384


  53 in total

1.  Subnuclear localization of Ku protein: functional association with RNA polymerase II elongation sites.

Authors:  Xianming Mo; William S Dynan
Journal:  Mol Cell Biol       Date:  2002-11       Impact factor: 4.272

2.  Nuclear actin: A key player in extracellular matrix-nucleus communication.

Authors:  Virginia A Spencer
Journal:  Commun Integr Biol       Date:  2011-09-01

3.  A phosphorylation switch regulates the transcriptional activation of cell cycle regulator p21 by histone deacetylase inhibitors.

Authors:  Elisabeth Simboeck; Anna Sawicka; Gordin Zupkovitz; Silvia Senese; Stefan Winter; Franck Dequiedt; Egon Ogris; Luciano Di Croce; Susanna Chiocca; Christian Seiser
Journal:  J Biol Chem       Date:  2010-10-14       Impact factor: 5.157

4.  Transcriptional regulation of HIV-1 gene expression by p53.

Authors:  Ruma Mukerjee; Pier Paolo Claudio; J Robert Chang; Luis Del Valle; Bassel E Sawaya
Journal:  Cell Cycle       Date:  2010-11-15       Impact factor: 4.534

5.  Fcp1 directly recognizes the C-terminal domain (CTD) and interacts with a site on RNA polymerase II distinct from the CTD.

Authors:  Man-Hee Suh; Ping Ye; Mincheng Zhang; Stéphane Hausmann; Stewart Shuman; Averell L Gnatt; Jianhua Fu
Journal:  Proc Natl Acad Sci U S A       Date:  2005-11-21       Impact factor: 11.205

6.  The carboxyl-terminal domain of RNA polymerase II is phosphorylated by a complex containing cdk9 and infected-cell protein 22 of herpes simplex virus 1.

Authors:  Lizette O Durand; Sunil J Advani; Alice P W Poon; Bernard Roizman
Journal:  J Virol       Date:  2005-06       Impact factor: 5.103

7.  Mechanisms involved in ceramide-induced cell cycle arrest in human hepatocarcinoma cells.

Authors:  Jing Wang; Xiao-Wen Lv; Jie-Ping Shi; Xiao-Song Hu
Journal:  World J Gastroenterol       Date:  2007-02-21       Impact factor: 5.742

8.  A role for Chk1 in blocking transcriptional elongation of p21 RNA during the S-phase checkpoint.

Authors:  Rachel Beckerman; Aaron J Donner; Melissa Mattia; Melissa J Peart; James L Manley; Joaquin M Espinosa; Carol Prives
Journal:  Genes Dev       Date:  2009-06-01       Impact factor: 11.361

9.  Optimization of non-ATP competitive CDK/cyclin groove inhibitors through REPLACE-mediated fragment assembly.

Authors:  Shu Liu; Padmavathy Nandha Premnath; Joshua K Bolger; Tracy L Perkins; Lindsay O Kirkland; George Kontopidis; Campbell McInnes
Journal:  J Med Chem       Date:  2013-02-12       Impact factor: 7.446

Review 10.  Cyclin-dependent kinase inhibitor drugs as potential novel anti-inflammatory and pro-resolution agents.

Authors:  A E Leitch; C Haslett; A G Rossi
Journal:  Br J Pharmacol       Date:  2009-09-23       Impact factor: 8.739

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.